Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer

Mark D. Pegram, MD
Published: Saturday, Feb 28, 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

There is debate about who should receive neoadjuvant treatment. Pegram says he believes that not everyone who has early-stage disease should receive neoadjuvant pertuzumab. Previous data have shown that a combination of 12 weekly doses of paclitaxel plus trastuzumab for a year demonstrated a 3-year projected disease-free survival rate of 98.7% in patients with stage I breast cancer. Pertuzumab couldn’t top this result, Pegram says.

For stage I disease, the combination of paclitaxel plus trastuzumab is arguable the most attractive treatment option in the adjuvant setting. If utilized, many patients would not need neoadjuvant therapy. ​

<<< View more from the 32nd Annual Miami Breast Cancer Conference

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

There is debate about who should receive neoadjuvant treatment. Pegram says he believes that not everyone who has early-stage disease should receive neoadjuvant pertuzumab. Previous data have shown that a combination of 12 weekly doses of paclitaxel plus trastuzumab for a year demonstrated a 3-year projected disease-free survival rate of 98.7% in patients with stage I breast cancer. Pertuzumab couldn’t top this result, Pegram says.

For stage I disease, the combination of paclitaxel plus trastuzumab is arguable the most attractive treatment option in the adjuvant setting. If utilized, many patients would not need neoadjuvant therapy. ​

<<< View more from the 32nd Annual Miami Breast Cancer Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x